dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Perkhofer, Lukas |
dc.contributor.author | Golan, Talia |
dc.contributor.author | Cuyle, Pieter-Jan |
dc.contributor.author | Matysiak-Budnik, Tamara |
dc.contributor.author | Van Laethem, Jean-Luc |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.date.accessioned | 2022-05-11T08:29:15Z |
dc.date.available | 2022-05-11T08:29:15Z |
dc.date.issued | 2021-08-24 |
dc.identifier.citation | Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Laethem JL Van, Macarulla T, et al. Targeting DNA Damage Repair Mechanisms in Pancreas Cancer. Cancers 2021. 2021 Aug 24;13(17):4259. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/7506 |
dc.description | BRCA1/2; PARP inhibition; Pancreatic ductal adenocarcinoma |
dc.description.abstract | Impaired DNA damage repair (DDR) is increasingly recognised as a hallmark in pancreatic ductal adenocarcinoma (PDAC). It is estimated that around 14% of human PDACs harbour mutations in genes involved in DDR, including, amongst others, BRCA1/2, PALB2, ATM, MSH2, MSH6 and MLH1. Recently, DDR intervention by PARP inhibitor therapy has demonstrated effectiveness in germline BRCA1/2-mutated PDAC. Extending this outcome to the significant proportion of human PDACs with somatic or germline mutations in DDR genes beyond BRCA1/2 might be beneficial, but there is a lack of data, and consequently, no clear recommendations are provided in the field. Therefore, an expert panel was invited by the European Society of Digestive Oncology (ESDO) to assess the current knowledge and significance of DDR as a target in PDAC treatment. The aim of this virtual, international expert meeting was to elaborate a set of consensus recommendations on testing, diagnosis and treatment of PDAC patients with alterations in DDR pathways. Ahead of the meeting, experts completed a 27-question survey evaluating the key issues. The final recommendations herein should aid in facilitating clinical practice decisions on the management of DDR-deficient PDAC. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;13(17) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pàncrees - Càncer - Prognosi |
dc.subject | ADN - Reparació |
dc.subject.mesh | Pancreatic Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | DNA Repair |
dc.subject.mesh | Prognosis |
dc.title | Targeting DNA Damage Repair Mechanisms in Pancreas Cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers13174259 |
dc.subject.decs | neoplasias pancreáticas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | reparación del ADN |
dc.subject.decs | pronóstico |
dc.relation.publishversion | https://doi.org/10.3390/cancers13174259 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Perkhofer L] Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany. [Golan T] Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel. [Cuyle PJ] Digestive Oncology Department, Imelda General Hospital, Bonheiden, Belgium. University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. [Matysiak-Budnik T] IMAD, Department of Gastroenterology and Digestive Oncology, Hôtel Dieu, CHU de Nantes, Nantes, France. [Van Laethem JL] GI Cancer Unit, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. [Macarulla T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34503069 |
dc.identifier.wos | 000694122200001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |